240 related articles for article (PubMed ID: 29748010)
1. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Jonker DJ; Tang PA; Kennecke H; Welch SA; Cripps MC; Asmis T; Chalchal H; Tomiak A; Lim H; Ko YJ; Chen EX; Alcindor T; Goffin JR; Korpanty GJ; Feilotter H; Tsao MS; Theis A; Tu D; Seymour L
Clin Colorectal Cancer; 2018 Sep; 17(3):231-239.e7. PubMed ID: 29653857
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Bernstein V; Ellard SL; Dent SF; Tu D; Mates M; Dhesy-Thind SK; Panasci L; Gelmon KA; Salim M; Song X; Clemons M; Ksienski D; Verma S; Simmons C; Lui H; Chi K; Feilotter H; Hagerman LJ; Seymour L
Breast Cancer Res Treat; 2018 Jan; 167(2):485-493. PubMed ID: 29027598
[TBL] [Abstract][Full Text] [Related]
4. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Noonan AM; Farren MR; Geyer SM; Huang Y; Tahiri S; Ahn D; Mikhail S; Ciombor KK; Pant S; Aparo S; Sexton J; Marshall JL; Mace TA; Wu CS; El-Rayes B; Timmers CD; Zwiebel J; Lesinski GB; Villalona-Calero MA; Bekaii-Saab TS
Mol Ther; 2016 Jun; 24(6):1150-1158. PubMed ID: 27039845
[TBL] [Abstract][Full Text] [Related]
9. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
13. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Mahalingam D; Wilkinson GA; Eng KH; Fields P; Raber P; Moseley JL; Cheetham K; Coffey M; Nuovo G; Kalinski P; Zhang B; Arora SP; Fountzilas C
Clin Cancer Res; 2020 Jan; 26(1):71-81. PubMed ID: 31694832
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
Moro-Sibilot D; Audigier-Valette C; Merle P; Quoix E; Souquet PJ; Barlesi F; Chouaid C; Molinier O; Bennouna J; Lavolé A; Mazières J; Toffart AC; Langlais A; Morin F; Zalcman G
Lung Cancer; 2015 Aug; 89(2):139-45. PubMed ID: 26059274
[TBL] [Abstract][Full Text] [Related]
19. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
